article thumbnail

The Gains and Pains of Using AI in the Pharmaceutical Industry

HIT Consultant

In addition to these challenges specific to their industry, pharma companies are all also presented with classic barriers to implementation. For example, the need for a flexible infrastructure to collect data, verify data, run applications, and perform data governance.

article thumbnail

COVID-19 Showcased Failed Global Cooperation

Bill of Health

Global solidarity requires cooperation between governments, while national solidarity involves cooperation within a state to address common challenges and achieve shared goals. Solidarity operates at two intersecting levels. That has created deep inequities in access to health products that can save lives.

COVID-19 299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

California Enters Insulin Manufacturing: Can We Expect to See a California Effect?

Bill of Health

By Aparajita Lath For over 100 years, policy makers and pharmaceutical manufacturers in the U.S. have debated whether the government should produce drugs and biologics. Until now, private industry has largely won– but that may be changing, due to a recent California initiative. Now, the tide is turning.

article thumbnail

The Case for Procurement Transparency

Bill of Health

Global health activists and civil society organizations who worked transnationally to curtail what came to be referred to as “vaccine apartheid” faced a pharmaceutical industry that globally relied on secrecy, capital-friendly trade laws, and brute economic force to shirk considerations of human rights.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

The selections feature topics ranging from an analysis of government and industry investments for recently approved drugs, to a discussion of court decisions on mifepristone, and an examination of the added therapeutic benefit associated with the top-selling brand-name drugs in Medicare. JAMA Health Forum. 2023 Apr 7;4(4):e230511.

article thumbnail

Drug Discovery Outsourcing Market Expected to Reach $7.5B by 2033

HIT Consultant

The research report on the drug discovery outsourcing market states that the pharmaceutical industry is expanding thoroughly with new extensions and high-end research programs. Moreover, the government projects and the bilateral relationship are also anticipated to increase drug production.

article thumbnail

Insights Management: A New Paradigm for Cancer Treatment

HIT Consultant

The field of cancer presents unique challenges for the pharmaceutical industry, requiring innovative solutions to address high demand, intense competition, expensive research and development (R&D), complexities in drug development, rapid introduction of new medicines, and the need for affordable access.